BIOLARGO, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3474 USD | -0.73% |
|
+2.30% | +106.79% |
| 02/04 | Transcript : BioLargo, Inc., Q4 2023 Earnings Call, Apr 02, 2024 | |
| 01/04 | BioLargo, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Commodity Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +106.79% | 104M | - | ||
| +5.92% | 104B | A- | ||
| -2.51% | 64.55B | A- | ||
| +51.90% | 41.5B | B | ||
| +18.29% | 40.01B | B | ||
| +7.69% | 33.03B | A- | ||
| +10.96% | 20.11B | B- | ||
| +16.99% | 17.52B | C+ | ||
| +20.27% | 15.51B | B- | ||
| +10.05% | 15.34B | B |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
- Stock Market
- Equities
- BLGO Stock
- Ratings BioLargo, Inc.